uniQure N.V (QURE)

Within the last quarter, uniQure (NASDAQ:QURE) has observed the following analyst ratings: Bullish Somewhat ...

If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, May 24, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) submitted by CSL Behring for etranacogene dezapar

LEXINGTON, Mass. and AMSTERDAM, May 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 32 newly hired employees as a material inducement to commencing their employment. The equity grants were approved on April 29, 2022 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the employees received

One thing we could say about the analysts on uniQure N.V. ( NASDAQ:QURE ) - they aren't optimistic, having just made a...

LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Hybrid Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C. "Our presentations at ASGCT showcase the exceptional work of our uniQu

uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

uniQure (NASDAQ:QURE) reported its Q1 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what investors need ...

~ Partner CSL Behring submitted Marketing Authorization Application (MAA) in Europe foretranacogene dezaparvovec in hemophilia B; MAA validated by the European Medicines Agency (EMA)and granted accelerated assessment ~ ~ Received $55 million in milestone payments associated with global submissions of marketing and license applications ~ ~ Completed patient enrollment of higher dose cohort of U.S. Phase I/II study of AMT-130 and lower dose cohort of European Phase Ib/II study; total of 32 patient

We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P 600 Small Cap Growth ETF (SLYG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $107.48 per unit.

The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. The industry includes smaller start-up companies with recent traction as well as large, well-established corporations that aim to develop a range of drugs and technologies.

Global biotherapeutics leader CSL Behring today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for etranacogene dezaparvovec (EtranaDez) under its accelerated assessment procedure. Etranacogene dezaparvovec is an investigational adeno-associated virus five (AAV5)-based gene therapy administered as a one-time treatment for hemophilia B patients with a severe bleeding phenotype. If approved, etranacogene dezaparvovec will provide peopl

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

LEXINGTON, Mass. and AMSTERDAM, March 21, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first two cohorts of its randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington’s disease. “We are very pleased to have completed the enrollment of the first 26 patients in this ongoin

Upgrades Loop Capital upgraded the previous rating for Aspen Technology Inc (NASDAQ:AZPN) from Hold to Buy. In the second quarter, ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard S&P Small-Cap 600 Growth ETF (VIOG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $270.22 per unit.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're almost done with the week but we still need to go over the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of complement (C5)NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems are implicated, today announced the appointment of Rachelle

uniQure (QURE) delivered earnings and revenue surprises of 123.61% and 129.68%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

uniQure (NASDAQ:QURE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors ...

~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-months and statistical superiority in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy; Submissions of marketing applications on track for the first half of 2022 ~ ~ Data from first four patients in ongoing U.S. Phase I/II clinical trial in Huntington’s Disease showed AMT-130 was well tolerated, with no significant safety concerns observed ~ ~ Additional clinical data f

A look at how the average stock that’s currently in the S&P 1500 has done since the Covid crash low by sector.

What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P SmallCap 600 QVM Multi-factor ETF (QVMS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $30.18 per unit.

LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease. The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany.

Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational adeno-associated virus five (AAV5)-based gene therapy for people living with hemophilia B, a life-threatening bleeding disorder. Following a single infusion of etranacogene dezaparvovec, participants experienced a stable and durable increase in mean Factor IX (FIX) activity and hemostatic protection at 18

Goshen, IN, based Investment company Everence Capital Management Inc (Current Portfolio) buys LyondellBasell Industries NV, Colgate-Palmolive Co, Match Group Inc, Activision Blizzard Inc, Merck Inc, sells CBRE Group Inc, JPMorgan Chase, Johnson Controls International PLC, The Estee Lauder Inc, Republic Services Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Everence Capital Management Inc.

uniQure (NASDAQ:QURE) has had a rough three months with its share price down 29%. However, stock prices are usually...